LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

47.6 5.97

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

46.94

Massimo

48.64

Metriche Chiave
By Trading Economics
Entrata	-14M -130M
Vendite	-888K 143K
Margine di Profitto	-90,972.727
Dipendenti	437
EBITDA	33K -129M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+66.63% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	645M 4.7B
Apertura precedente	41.63
Chiusura precedente	47.6

Notizie sul Sentiment di mercato

By Acuity

15%

85%

16 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 dic 2025, 17:29 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 dic 2025, 16:47 UTC

I principali Market Mover

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 dic 2025, 16:10 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19 dic 2025, 22:33 UTC

Utili

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 dic 2025, 22:19 UTC

Utili

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 dic 2025, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dic 2025, 21:44 UTC

Utili

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dic 2025, 21:38 UTC

Utili

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 dic 2025, 21:00 UTC

Discorsi di Mercato

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 dic 2025, 20:23 UTC

Discorsi di Mercato

Oil Futures End Down Week on Up Note -- Market Talk

19 dic 2025, 20:14 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 dic 2025, 18:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 dic 2025, 18:00 UTC

Discorsi di Mercato

Utili

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 dic 2025, 17:41 UTC

Utili

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dic 2025, 17:24 UTC

Discorsi di Mercato

Utili

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 dic 2025, 17:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

19 dic 2025, 17:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

19 dic 2025, 16:29 UTC

Utili

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 dic 2025, 16:20 UTC

Acquisizioni, Fusioni, Takeovers

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 dic 2025, 16:19 UTC

Acquisizioni, Fusioni, Takeovers

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 dic 2025, 16:18 UTC

Acquisizioni, Fusioni, Takeovers

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 dic 2025, 16:16 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

19 dic 2025, 16:16 UTC

Discorsi di Mercato

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 dic 2025, 16:05 UTC

Acquisizioni, Fusioni, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dic 2025, 16:04 UTC

Acquisizioni, Fusioni, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dic 2025, 15:37 UTC

Discorsi di Mercato

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 dic 2025, 15:21 UTC

Discorsi di Mercato

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 dic 2025, 15:09 UTC

Discorsi di Mercato

Gold Flat But Set for Weekly Gains -- Market Talk

19 dic 2025, 15:09 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

19 dic 2025, 15:09 UTC

Utili

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

66.63% in crescita

Previsioni per 12 mesi

Media 80 USD 66.63%

Alto 108 USD

Basso 45 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 15 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

16 / 374 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.